Entera Bio announces PK data from oral GLP-2 peptide tablet treatment

Entera Bio (ENTX) announced positive pharmacokinetic, PK, results from its collaborative research combining a proprietary long acting GLP-2 agonist developed by OPKO Health (OPK) with Entera’s proprietary N-Tab technology. Entera and OPKO completed a proof of concept single dose pharmacokinetic study in rodents as the first validation for oral administration of the GLP-2 treatment. “Given the challenging compliance rates attributed to injectable GLP-2 therapy, we believe a daily tablet format may address a significant unmet need in treating SBS patients more effectively. We are pleased with this first validation for the oral GLP-2 peptide program that we initiated in late 2023 in our collaboration with OPKO. The current PK data reinforces the data we previously published combining our N-Tab technology with teduglutide in tablet form1. Based on the promising results from the current PK study, we are planning to advance the program to assess pharmacologic effects in vivo. We look forward to updating on these data later in 2024,” said Miranda Toledano, Entera Chief Executive Officer.